Bagsværd, Denmark, 31 January 2024 - Novo Nordisk's (NYSE: NVO) sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
Operating profit increased by 37% in Danish kroner and by 44% at constant exchange rates (CER) to DKK 102.6 billion.
PROFIT AND LOSS | 2023 | 2022 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 232,261 | 176,954 | 31% | 36% |
Operating profit | 102,574 | 74,809 | 37% | 44% |
Net profit | 83,683 | 55,525 | 51% | N/A |
Diluted earnings per share (in DKK) | 18.62 | 12.22 | 52% | N/A |
* CER: Constant exchange rates (average 2022). |
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the strong performance in 2023 reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments. We continue to make progress on our strategic aspirations. Our focus in 2024 will be on reaching more patients, progressing and expanding our pipeline as well as the continued significant expansion of our production capacity."
On 31 January 2024 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
Financial calendar | ||
7 March 2024 | Capital Markets Day 2024 in Copenhagen | |
21 March 2024 | Annual General Meeting | |
2 May 2024 | Financial results for the first three months of 2024 | |
7 August 2024 | Financial results for the first half of 2024 | |
6 November 2024 | Financial results for the first nine months of 2024 |
Novo Nordisk’s Annual Report 2023 is available at https://www.novonordisk.com/investors/annual-report.html and attached in iXBRL format.
Last Trade: | US$131.14 |
Daily Change: | 0.25 0.19 |
Daily Volume: | 2,569,667 |
Market Cap: | US$443.250B |
July 10, 2024 June 24, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB